Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • He, Y. X.
  • Zhou, Y. S.
  • Liu, S. W.
  • Kou, Z. H.
  • Li, W. H.
  • Farzan, Michael
  • Jiang, S. B.

publication date

  • November 2004

journal

  • Biochemical and Biophysical Research Communications  Journal

abstract

  • The spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (CoV), a type I transmembrane envelope glycoprotein, consists of S1 and S2 domains responsible for virus binding and fusion, respectively. The S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. Here we show that a recombinant fusion protein (designated RBD-Fc) containing 193-amino acid RBD (residues 318-510) and a human IgG1 Fc fragment can induce highly potent antibody responses in the immunized rabbits. The antibodies recognized RBD on S1 domain and completely inhibited SARS-CoV infection at a serum dilution of 1:10,240. Rabbit antisera effectively blocked binding of S1, which contains RBD, to ACE2. This suggests that RBD can induce highly potent neutralizing antibody responses and has potential to be developed as an effective and safe subunit vaccine for prevention of SARS.

subject areas

  • Animals
  • Antibodies
  • Cell Line
  • Dose-Response Relationship, Immunologic
  • Enzyme-Linked Immunosorbent Assay
  • Flow Cytometry
  • Humans
  • Immunoglobulin Fragments
  • Immunoglobulin G
  • Membrane Glycoproteins
  • Plasmids
  • Protein Structure, Tertiary
  • Rabbits
  • Recombinant Fusion Proteins
  • Spike Glycoprotein, Coronavirus
  • Vaccines
  • Viral Envelope Proteins
scroll to property group menus

Research

keywords

  • SARS-CoV
  • neutralizing antibody
  • receptor-binding domain
  • spike protein
  • vaccine
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0006-291X

Digital Object Identifier (DOI)

  • 10.1016/j.bbrc.2004.09.106

PubMed ID

  • 15474494
scroll to property group menus

Additional Document Info

start page

  • 773

end page

  • 781

volume

  • 324

issue

  • 2

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support